Artículos por temáticas

[A Therapeutic Target for Inhibition of Neurodegeneration: Autophagy]

Pupyshev AB, Korolenko TA, Tikhonova MA.

Zh Vyssh Nerv Deiat Im I P Pavlova. 2016 Sep;66(5):515-540.

The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease

Grizzanti J, Lee HG, Camins A, Pallas M, Casadesus G.

Nutr Res. 2016 Dec;36(12):1305-1315. doi: 10.1016/j.nutres.2016.11.002. Epub 2016 Nov 8.

Phage M13 for the treatment of Alzheimer and Parkinson disease

Messing J.

Gene. 2016 Jun 1;583(2):85-89. doi: 10.1016/j.gene.2016.02.005. Epub 2016 Feb 8.

[Immunotherapy is a possible treatment for future Alzheimer’s disease patients]

Lolk A.

Ugeskr Laeger. 2016 Jun 13;178(24):V68110.

Pressure ulcers induced by drug administration: A new concept and report of four cases in elderly patients

Mizokami F, Takahashi Y, Hasegawa K, Hattori H, Nishihara K, Endo H, Furuta K, Isogai Z.

J Dermatol. 2016 Apr;43(4):436-8. doi: 10.1111/1346-8138.13093. Epub 2015 Sep 14.

A comparative study of caregiver burden in late-onset depression and Alzheimer's disease

Kazhungil F, Velayudhan R, Kumar M, Thazhe Mangool R.

Psychogeriatrics. 2016 May;16(3):209-15. doi: 10.1111/psyg.12141. Epub 2015 Jul 16.

Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial

Homma A, Atarashi H, Kubota N, Nakai K, Takase T.

J Alzheimers Dis. 2016 Mar 11;52(1):345-57. doi: 10.3233/JAD-151149.

The Savvy Caregiver Program: A Probe Multicenter Randomized Controlled Pilot Trial in Caregivers of Patients Affected by Alzheimer's Disease

Sepe-Monti M, Vanacore N, Bartorelli L, Tognetti A, Giubilei F; Caregiver Study Group Savvy.

J Alzheimers Dis. 2016 Oct 4;54(3):1235-1246. doi: 10.3233/JAD-160235.

[Development of Disease-modifying Therapy for Alzheimer's Disease]

Akiyama H.

Brain Nerve. 2016 Apr;68(4):463-72. doi: 10.11477/mf.1416200419.

Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer's Disease

Prati F, Cavalli A, Bolognesi ML.

Molecules. 2016 Apr 8;21(4):466. doi: 10.3390/molecules21040466.

Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit

Molinuevo JL, Cami J, Carné X, Carrillo MC, Georges J, Isaac MB, Khachaturian Z, Kim SY, Morris JC, Pasquier F, Ritchie C, Sperling R, Karlawish J.

Alzheimers Dement. 2016 May;12(5):614-22. doi: 10.1016/j.jalz.2016.01.009. Epub 2016 Mar 15.

Serotonergic Drugs: Agonists/Antagonists at Specific Serotonergic Subreceptors for the Treatment of Cognitive, Depressant and Psychotic Symptoms in Alzheimer's Disease

Werner FM, Covenas R.

Curr Pharm Des. 2016;22(14):2064-71. doi: 10.2174/1381612822666160127113524.

Spanish validation of the Person-centered Care Assessment Tool (P-CAT)

Martínez T, Suárez-Álvarez J, Yanguas J, Muñiz J.

Aging Ment Health. 2016;20(5):550-8. doi: 10.1080/13607863.2015.1023768. Epub 2015 Mar 26.

Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer's disease: interim results from the long-term, large-scale J-GOLD study in Japan

Arai H, Sumitomo K, Sakata Y, Daidoji K, Takase T, Toyoda T.

Psychogeriatrics. 2016 Mar;16(2):107-15. doi: 10.1111/psyg.12130. Epub 2015 Jun 26.

Efficacy of Ginkgo biloba extract EGb 761(®) in dementia with behavioural and psychological symptoms: A systematic review

von Gunten A, Schlaefke S, Überla K.

World J Biol Psychiatry. 2016 Dec;17(8):622-633. doi: 10.3109/15622975.2015.1066513. Epub 2015 Jul 30.